Issues of use of hepatoprotectors in psoriasis: Indications and effectiveness

Abstract

The pathology of the hepatobiliary system in psoriasis may be the result of taking hepatotoxic drugs, the result of a systemic inflammatory process. In this connection, it is necessary to consider the issue of including hepatoprotective drugs in psoriasis treatment regimens. There were 69 patients under observation, which, depending on the severity and prescribed treatment, were divided into 4 groups. In the B1A subgroup, a 75% reduction in PASI was observed in all patients, with PASI100 reaching 87.5% of patients. In subgroup 1B, a 75% decrease in PASI was observed in 87.5% of patients, while PASI100 reached 68.7% of patients. The DIQI index reduced in the 1A subgroup by 72.9%, in the 1B subgroup – by 66.3%. All patients of group 1 were diagnosed with non-alcoholic fatty liver disease. After therapy, in patients of subgroup 1A (therapy included a course of phosphogliv), the number of transaminases signifcantly decreased, in subgroup 1B there was no dynamics. In subgroup 2A, a 75% decrease in PASI was observed in 90% of patients, while PASI100 reached 60.0% of patients. In subgroup 2B, a 75% decrease in PASI was observed in 70.6% of patients, while PASI100 reached 47.1% of patients. The DIQI index reduced in the 2A subgroup by 77.0%, in the 2B subgroup – by 60.2%. The inclusion of phosphogliv in the therapeutic complex can increase the effectiveness of the treatment and reduce the risk of developing druginduced liver damage against the background of the use of potentially hepatotoxic drugs.